

APR 2 7 2000

FILE: A31967-PCT-USA-A (066031.0102)

TECH CENTER 1600/2900

**PATENT** 

Page 37, line 27, cancel "NO:4," insert -- NO:3 --.

Page 56, line 6, cancel NO:3," insert -- NO:4 --.

Page 56, line 7, cancel "NO:4," insert -- NO:3 --.

## **REMARKS**

This supplemental amendment is intended to correct obvious inadvertent typographical errors in the specification. In addition, enclosed herewith please also find a new Sequence Listing in both paper and computer readable form, incorporating the changes made by the amendment, together with the necessary Declaration.

By this amendment, SEQ ID NO:3 and SEQ ID NO:4 designations have been amended such that SEQ ID NO:4 represents the peptide corresponding to amino acid residues 152-161 of the naturally occurring SEB protein and SEQ ID NO:3 represents the peptide corresponding to a peptide variant of the naturally occurring SEB protein. The amendments conform with the descriptions found throughout the specification.

Support for the amendments may be found, *inter alia*, on page 53, in Table 2, which indicates that the sequence KKKATVQELD is a <u>variant</u> of the natural protein. Further support may be found in pages 21 through 22, where it is clearly indicated that the peptide pSEB (152-161) comprises an amino acid sequence corresponding to the naturally occurring protein, whereas the peptide p10 (152-161) is a variant thereof. In addition, support for this obvious error may be found on page 37, where it is clearly stated that p10 (152-161) lacks the 2 N-terminal amino acids of p12 (152-161).

FILE: A31967-PCT-USA-A (066031.0102)

**PATENT** 

Similar amendments were accepted by the Examining Authority during National Phase of the corresponding PCT application No. PCT/IL97/00438.

Also attached herewith is a copy of the International Preliminary

Examination Report (IPER). The IPER indicates that all pending claims in the

corresponding PCT application PCT/IL97/00438, including those subject to restriction
requirement herein have been found to have novelty, inventive step and industrial
applicability.

Applicants request that the aforementioned amendments, that correct obvious inadvertent typographical errors, and the attached International Preliminary Examination Report be made of record in the above-referenced patent application and that the amendment be entered as it does not constitute new matter.

No fee is believed required, however, the Commissioner is hereby authorized to charge payment of any additional fee to Deposit Account No. 02-4377.

Respectfully submitted,

Rochelle K. Seide

Patent Office Reg. No. 32,300

Attorney for Applicants (212) 408-2626

Alicia A. Russo Patent Office Reg. No. 46,192

Agent for Applicants (212)408-2627